Atenolol Market Size & Share, by Form (Tablets, IV Solution); Dosage Type (25mg, 50mg, 100 mg); Application (Hypertension, Angina, Arrhythmia); Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4076
  • Published Date: Apr 03, 2023
  • Report Format: PDF, PPT

Companies Dominating the Atenolol Landscape

top-features-companies
    • Intas Pharmaceuticals Limited
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Abbott Laboratories
    • F. Hoffmann-La Roche Ltd
    • Danaher Corporation
    • Bio-Rad Laboratories, Inc.
    • Sysmex Corporation
    • Zydus Pharmaceuticals (USA) Inc.
    • Ipca Laboratories Limited
    • Unichem Laboratories Limited
    • AstraZeneca PLC

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Unichem Laboratories Limited obtained ANDA authorization from the United States Food and Drug Administration (USFDA) for its Atenolol and Chlorthalidone Tablets, USP 50 mg/25 mg and 100 mg/25 mg to be sold as a generic version of Alvogen Malta Operations Ltd's TENORETIC (atenolol and chlorthalidone) Tablets.

  • AstraZeneca PLC has approved the sale of the worldwide commercial rights Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril), and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma. This deal has eliminated the already sold rights in the United States and India, as well as the rights in Japan, which will be kept by AstraZeneca.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4076
  • Published Date: Apr 03, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of angina experiences, expansion in sedentary lifestyle, and increasing prevalence of arrhythmia are the major factors driving the market growth.

The market size of atenolol is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2023-2035.

Associated side effects of atenolol, availability of diuretics and other drugs, and risk of interaction with other drugs are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Intas Pharmaceuticals Limited, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Bio-Rad Laboratories, Inc., Sysmex Corporation, Ipca Laboratories Limited, and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by form, dosage type, application, distribution channel, and by region.

The hypertension segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying